Key result
Revascularization cuts annual mortality ~80% vs. medical therapy in CAD with LV dysfunction and viability.
Why the study?
Previous observational studies suggested survival benefit from revascularization in patients with severe CAD and LV dysfunction when myocardial viability is detected, but pooled data were needed.
Does revascularization reduce annual mortality compared with medical therapy in patients with severe coronary artery disease and left ventricular dysfunction who undergo myocardial viability testing?
Meta-Analysis (n=3,088)
Does revascularization reduce annual mortality compared with medical therapy in patients with severe coronary artery disease and left ventricular dysfunction who undergo myocardial viability testing?
Answers are grounded in this paper and cite their sources.
This meta-analysis demonstrates that myocardial viability detected on noninvasive imaging is strongly associated with a 79.6% reduction in annual mortality after revascularization compared to medical therapy in patients with chronic CAD and LV dysfunction, whereas patients without viability derive no significant survival benefit from revascularization.
OBJECTIVES: This study pools data from published series examining late survival with revascularization versus medical therapy after myocardial viability testing in patients with severe coronary artery disease (CAD) and left ventricular (LV) dysfunction. BACKGROUND: Previous observational studies have suggested survival benefit in such patients if they are revascularized when myocardial viability is detected on imaging tests. METHODS: A MEDLINE database search returned 24 viability studies reporting patient survival using thallium perfusion imaging, F-18 fluorodeoxyglucose metabolic imaging or dobutamine echocardiography. Annual death rates were extracted, pooled and analyzed with a random effects model. The risk-adjusted relationship between severity of LV dysfunction, presence of viability and survival benefit associated with revascularization was assessed by meta-regression. RESULTS: There were 3,088 patients (2,228 men), ejection fraction 32 +/- 8%, followed for 25 +/- 10 months. In patients with viability, revascularization was associated with 79.6% reduction in annual mortality (16% vs. 3.2%, chi-square = 147, p < 0.0001) compared with medical treatment. Patients without viability had intermediate mortality, trending to higher rates with revascularization versus medical therapy (7.7% vs. 6.2%, p = NS). Patients with viability showed a direct relationship between severity of LV dysfunction and magnitude of benefit with revascularization (p < 0.001). There was no measurable performance difference for predicting revascularization benefit between the three testing techniques. CONCLUSIONS: This meta-analysis demonstrates a strong association between myocardial viability on noninvasive testing and improved survival after revascularization in patients with chronic CAD and LV dysfunction. Absence of viability was associated with no significant difference in outcomes, irrespective of treatment strategy.
No takes yet. Share an insight, caveat, or question.
Allman et al. (2002) conducted a meta-analysis in severe coronary artery disease and left ventricular dysfunction (n=3,088). Revascularization vs. Medical therapy was evaluated on Annual mortality (79.6% reduction, p=< 0.0001). In patients with CAD, LV dysfunction, and myocardial viability, revascularization reduced annual mortality compared with medical therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: